Terug
32
Ook genoteerd als
CHEOY
OTC
Dagbereik
€ 116,81
€ 116,81
52-Weeksbereik
€ 116,81
€ 207,71
Volume
6.995
50D / 200D Gem.
€ 181,02
/
€ 185,43
Vorige Slotkoers
€ 123,96
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 19,6 | 0,4 |
| P/B | 3,9 | 2,9 |
| ROE % | 20,5 | 3,7 |
| Net Margin % | 16,6 | 3,9 |
| Rev Growth 5Y % | 11,8 | 10,0 |
| D/E | 0,1 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 11,53
€ 10,93 – € 12,27
|
2,5 B | 1 |
| FY2029 |
€ 10,69
€ 10,14 – € 11,38
|
3,7 B | 1 |
| FY2028 |
€ 8,50
€ 8,06 – € 9,05
|
3,2 B | 1 |
Belangrijkste Punten
Revenue grew 11,84% annually over 5 years — strong growth
ROE of 20,52% indicates high profitability
Net margin of 16,60% shows strong profitability
Debt/Equity of 0,12 — conservative balance sheet
Generating 135,00M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,03%
Groei
Revenue Growth (5Y)
11,84%
Revenue (1Y)4,81%
Earnings (1Y)9,00%
FCF Growth (3Y)-28,83%
Kwaliteit
Return on Equity
20,52%
ROIC13,93%
Net Margin16,60%
Op. Margin17,33%
Veiligheid
Debt / Equity
0,12
Current Ratio2,35
Interest Coverage36,92
Waardering
P/E Ratio
19,64
P/B Ratio3,92
EV/EBITDA18,71
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4,81% | Revenue Growth (3Y) | 10,01% |
| Earnings Growth (1Y) | 9,00% | Earnings Growth (3Y) | 13,74% |
| Revenue Growth (5Y) | 11,84% | Earnings Growth (5Y) | 4,47% |
| Profitability | |||
| Revenue (TTM) | 2,34B | Net Income (TTM) | 388,90M |
| ROE | 20,52% | ROA | 13,77% |
| Gross Margin | 73,74% | Operating Margin | 17,33% |
| Net Margin | 16,60% | Free Cash Flow (TTM) | 135,00M |
| ROIC | 13,93% | FCF Growth (3Y) | -28,83% |
| Safety | |||
| Debt / Equity | 0,12 | Current Ratio | 2,35 |
| Interest Coverage | 36,92 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 19,64 | P/B Ratio | 3,92 |
| P/S Ratio | 3,26 | PEG Ratio | 5,17 |
| EV/EBITDA | 18,71 | Dividend Yield | 0,02% |
| Market Cap | 7,64B | Enterprise Value | 7,60B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,34B | 2,24B | 1,94B | 1,65B | 1,50B |
| Net Income | 388,90M | 356,80M | 300,60M | 289,10M | 326,50M |
| EPS (Diluted) | 5,93 | 5,43 | 4,56 | 4,40 | 4,93 |
| Gross Profit | 1,73B | 1,67B | 1,45B | 1,24B | 1,09B |
| Operating Income | 406,10M | 475,00M | 389,50M | 402,40M | 370,20M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,83B | 2,75B | 2,57B | 2,47B | 2,44B |
| Total Liabilities | 874,70M | 904,60M | 819,90M | 779,40M | 736,50M |
| Shareholders' Equity | 1,95B | 1,84B | 1,75B | 1,69B | 1,70B |
| Total Debt | 235,70M | 243,70M | 201,80M | 253,90M | 264,30M |
| Cash & Equivalents | 275,70M | 513,60M | 555,50M | 629,30M | 609,60M |
| Current Assets | 1,42B | 1,45B | 1,36B | 1,33B | 1,23B |
| Current Liabilities | 602,30M | 631,50M | 578,00M | 527,60M | 402,50M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#154 of 195
Recente Activiteit
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026